CEN BIOTECH INC
company.status.inactiveCIK 1653821fmd_1CSAHGHY1QCAJQV63ZC69KRGDGManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2014 to Sep 30, 2022, 32 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 0 | 0 | – | – | 0 | 1 |
| Research and development | – | – | – | 0 | 0 | 0 | 0 | 0 |
| Compensation and benefits | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Total operating expenses | 3 | 1 | 7 | 12 | 4 | 3 | 3 | 20 |
| Impairment of real estate | – | – | 1 | 0 | 0 | 0 | 0 | 0 |
| Operating income | (3) | (1) | (7) | (12) | (4) | (3) | (3) | (19) |
| Interest expense | 0 | 1 | 1 | 2 | 2 | 3 | 3 | 0 |
| Other non-operating income (expense) | – | (1) | (2) | (2) | (3) | (3) | 17 | 0 |
| Income before taxes | – | – | – | – | – | – | 14 | (19) |
| Income tax expense | 0 | 0 | 0 | – | – | – | 0 | (0) |
| Net income from continuing operations | – | – | – | – | – | – | 14 | (19) |
| Net income | (3) | (2) | (8) | (14) | (8) | (6) | 14 | (19) |
| Net income to common shareholders | – | – | – | – | – | – | 14 | 1 |